Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chengdu Kangnuoxing Biopharma, Inc.
Chengdu, Sichuan Sheng, Chinakeymedbio.com ↗
- Ownership
- Private
- Employees
- ~900
- Development stage
- Commercial
01
Overview
Stapokibart (CM310), an anti–IL‑4Rα monoclonal antibody developed by the company, has been approved in China for chronic rhinosinusitis with nasal polyps. The company is also running Phase III trials for atopic dermatitis and nodular prurigo. Additional assets are in earlier clinical or preclinical development targeting autoimmune diseases and oncology.
- Therapeutic areas
- OncologyDermatologyImmunologyNeurology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodiesAntibody-drug conjugates (ADCs)Small nucleic acids
- Industry
- Biotech
02
Partnerships
Collaborations with other pharmaceutical & biotech companies via parent company platforms; specifics not detailed.
Beyond the preview
Go deeper on Chengdu Kangnuoxing Biopharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Kangnuoxing Biopharma, Inc..